BRAIN Biotech posts Q1 net loss of EUR 2.9 million, revenue down 9% to EUR 11.9 million

Reuters02-25 14:30

BRAIN Biotech posts Q1 net loss of EUR 2.9 million, revenue down 9% to EUR 11.9 million

BRAIN Biotech reported Q1 FY 2025/26 revenue of EUR 11.9 million, down 9.0%, with total operating performance of EUR 13.0 million. Adjusted EBITDA was EUR 0.3 million, while EBITDA was EUR -0.3 million and EBIT was EUR -1.5 million. Net loss for the period was EUR 2.9 million, with EPS (basic and diluted) of EUR -0.13. In BRAINBiocatalysts, Q1 revenue was EUR 10.0 million (-16.3%) and adjusted EBITDA was EUR 0.5 million, with the company citing low sales momentum in baking enzymes and production interruptions tied to the relocation of production facilities to a new joint site in the Netherlands. BRAINBioIncubator Q1 revenue was EUR 1.9 million, supported by a EUR 1.0 million milestone payment related to the deucrictibant project; the company also noted that license and monetization agreements with Pharvaris and Royalty Pharma have generated EUR 3.3 million in milestone payments so far in FY 2025/26, including EUR 2.3 million received as cash inflow in Q1. Cash and cash equivalents were EUR 5.1 million at 31 December 2025 (from EUR 6.2 million at 30 September 2025).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BRAIN Biotech AG published the original content used to generate this news brief on February 25, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614877051?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-25 14:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614877051","market":"fut","top_or_hot":-1,"title":"BRAIN Biotech posts Q1 net loss of EUR 2.9 million, revenue down 9% to EUR 11.9 million","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BRAIN Biotech posts Q1 net loss of EUR 2.9 million, revenue down 9% to EUR 11.9 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BRAIN Biotech reported Q1 FY 2025/26 revenue of EUR 11.9 million, down 9.0%, with total operating performance of EUR 13.0 million. Adjusted EBITDA was EUR 0.3 million, while EBITDA was EUR -0.3 million and EBIT was EUR -1.5 million. Net loss for the period was EUR 2.9 million, with EPS (basic and diluted) of EUR -0.13. In BRAINBiocatalysts, Q1 revenue was EUR 10.0 million (-16.3%) and adjusted EBITDA was EUR 0.5 million, with the company citing low sales momentum in baking enzymes and production interruptions tied to the relocation of production facilities to a new joint site in the Netherlands. BRAINBioIncubator Q1 revenue was EUR 1.9 million, supported by a EUR 1.0 million milestone payment related to the deucrictibant project; the company also noted that license and monetization agreements with Pharvaris and Royalty Pharma have generated EUR 3.3 million in milestone payments so far in FY 2025/26, including EUR 2.3 million received as cash inflow in Q1. Cash and cash equivalents were EUR 5.1 million at 31 December 2025 (from EUR 6.2 million at 30 September 2025).\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BRAIN Biotech AG published the original content used to generate this news brief on February 25, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRAIN Biotech posts Q1 net loss of EUR 2.9 million, revenue down 9% to EUR 11.9 million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRAIN Biotech posts Q1 net loss of EUR 2.9 million, revenue down 9% to EUR 11.9 million\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-25 14:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      BRAIN Biotech posts Q1 net loss of EUR 2.9 million, revenue down 9% to EUR 11.9 million\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BRAIN Biotech reported Q1 FY 2025/26 revenue of EUR 11.9 million, down 9.0%, with total operating performance of EUR 13.0 million. Adjusted EBITDA was EUR 0.3 million, while EBITDA was EUR -0.3 million and EBIT was EUR -1.5 million. Net loss for the period was EUR 2.9 million, with EPS (basic and diluted) of EUR -0.13. In BRAINBiocatalysts, Q1 revenue was EUR 10.0 million (-16.3%) and adjusted EBITDA was EUR 0.5 million, with the company citing low sales momentum in baking enzymes and production interruptions tied to the relocation of production facilities to a new joint site in the Netherlands. BRAINBioIncubator Q1 revenue was EUR 1.9 million, supported by a EUR 1.0 million milestone payment related to the deucrictibant project; the company also noted that license and monetization agreements with Pharvaris and Royalty Pharma have generated EUR 3.3 million in milestone payments so far in FY 2025/26, including EUR 2.3 million received as cash inflow in Q1. Cash and cash equivalents were EUR 5.1 million at 31 December 2025 (from EUR 6.2 million at 30 September 2025).\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BRAIN Biotech AG published the original content used to generate this news brief on February 25, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PHVS","symbol_name":"Pharvaris N.V.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDL5DmRdQ:1","article_id":"2614877051","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614877051","pubTimestamp":1772001047,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRAIN Biotech reported Q1 FY 2025/26 revenue of EUR 11.9 million, down 9.0%, with total operating performance of EUR 13.0 million. Adjusted EBITDA was EUR 0.3 million, while EBITDA was EUR -0.3 million and EBIT was EUR -1.5 million. Net loss for the period was EUR 2.9 million, with EPS  of EUR -0.13. In BRAINBiocatalysts, Q1 revenue was EUR 10.0 million  and adjusted EBITDA was EUR 0.5 million, with the company citing low sales momentum in baking enzymes and production interruptions tied to the relocation of production facilities to a new joint site in the Netherlands. BRAINBioIncubator Q1 revenue was EUR 1.9 million, supported by a EUR 1.0 million milestone payment related to the deucrictibant project; the company also noted that license and monetization agreements with Pharvaris and Royalty Pharma have generated EUR 3.3 million in milestone payments so far in FY 2025/26, including EUR 2.3 million received as cash inflow in Q1. Cash and cash equivalents were EUR 5.1 million at 31 Dece","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PHVS":"Pharvaris N.V.","RPRX":"Royalty Pharma plc","BK4007":"制药"},"translate_title":"BRAIN Biotech第一季度净亏损290万欧元，收入下降9%至1190万欧元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RPRX":0.9,"PHVS":0.9},"content_text":"BRAIN Biotech posts Q1 net loss of EUR 2.9 million, revenue down 9% to EUR 11.9 million\n    \n\n        BRAIN Biotech reported Q1 FY 2025/26 revenue of EUR 11.9 million, down 9.0%, with total operating performance of EUR 13.0 million. Adjusted EBITDA was EUR 0.3 million, while EBITDA was EUR -0.3 million and EBIT was EUR -1.5 million. Net loss for the period was EUR 2.9 million, with EPS (basic and diluted) of EUR -0.13. In BRAINBiocatalysts, Q1 revenue was EUR 10.0 million (-16.3%) and adjusted EBITDA was EUR 0.5 million, with the company citing low sales momentum in baking enzymes and production interruptions tied to the relocation of production facilities to a new joint site in the Netherlands. BRAINBioIncubator Q1 revenue was EUR 1.9 million, supported by a EUR 1.0 million milestone payment related to the deucrictibant project; the company also noted that license and monetization agreements with Pharvaris and Royalty Pharma have generated EUR 3.3 million in milestone payments so far in FY 2025/26, including EUR 2.3 million received as cash inflow in Q1. Cash and cash equivalents were EUR 5.1 million at 31 December 2025 (from EUR 6.2 million at 30 September 2025).\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BRAIN Biotech AG published the original content used to generate this news brief on February 25, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614877051","isCrawlerRequest":true}